Dr. Daan DETROYER Nefrologie
Dr. Daan DETROYER Nefrologie has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €35k and a net result of €316k. Equity is shrinking by ~54% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2026. Its solvency ranks better than 22% of 2224 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
| Equity | €35k |
| Net result | €316k |
| Better than sector | 22% |
| Active | 10 yrs |
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 9.6% | 57.9% | |
| Net result | €316k | €59k | |
| Equity | €35k | €74k | |
| Gross operating margin | €417k | €95k | |
| Total assets | €364k | €187k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | micro schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | €415k | €293k | €285k | €408k |
| Net profit | €316k | €218k | €208k | €302k |
| Cash flow | €316k | €225k | €218k | €311k |
| Staff costs | - | - | - | - |
| Income taxes | €100k | €67k | €66k | €97k |
| Dividends | €645k | €650k | - | - |
| Total assets | €364k | €367k | €822k | €624k |
| Equity | €35k | €364k | €796k | €588k |
| Debt | €329k | €2k | €26k | €36k |
| of which ≤ 1y | €328k | €2k | €26k | €36k |
| of which > 1y | - | - | - | - |
| Working capital | €36k | €364k | €789k | €571k |
| Employees (FTE) | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 1.11 | 146.93 | 31.48 | 16.80 |
| Quick ratio | 1.11 | 146.93 | 31.48 | 16.80 |
| Working capital ratio | 9.9% | 99.3% | 96.0% | 91.6% |
| Solvency | 9.6% | 99.3% | 96.8% | 94.2% |
| Debt / equity | 9.41 | 0.01 | 0.03 | 0.06 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 2152.57 | 5189.60 | 185.31 | 10463.09 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 86.8% | 59.5% | 25.4% | 48.4% |
| ROE | 903.4% | 59.9% | 26.2% | 51.4% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (22 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €364k | €367k | €822k | €624k |
| Fixed assets | 21/28 | - | €0 | €7k | €16k |
| Tangible fixed assets | 22/27 | - | €0 | €7k | €16k |
| Current assets | 29/58 | €364k | €367k | €815k | €608k |
| Amounts receivable within one year | 40/41 | €7k | €126k | €54k | - |
| Cash & bank | 54/58 | €251k | €141k | €672k | €486k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €364k | €367k | €822k | €624k |
| Equity | 10/15 | €35k | €364k | €796k | €588k |
| Contributions / capital | 10/11 | €19k | €19k | €19k | €19k |
| Reserves | 13 | €16k | €346k | €777k | €569k |
| Accumulated profits (losses) | 14 | €0 | €0 | - | - |
| Amounts payable | 17/49 | €329k | €2k | €26k | €36k |
| Amounts payable within one year | 42/48 | €328k | €2k | €26k | €36k |
| Trade debts payable within one year | 44 | €3k | €2k | €1k | €5k |
| Income statement | |||||
| Gross operating margin | 9900 | €417k | €294k | €287k | €409k |
| Operating result | 9901 | €415k | €286k | €276k | €399k |
| Financial income | 75 | €0 | €31 | - | - |
| Financial charges | 65 | €193 | €56 | €2k | €39 |
| Result before taxes | 9903 | €415k | €286k | €274k | €399k |
| Income taxes | 67/77 | €100k | €67k | €66k | €97k |
| Net result for the period | 9904 | €316k | €218k | €208k | €302k |
| Result to be appropriated | 9905 | €316k | €218k | €208k | €302k |
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 01-08-2016 |
| Status | Active |
| Postal code | 2240 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71053G0266/00N003 | Flanders | 4.1 ha | 1 · 9,813 m² | 24.2 m · 5 fl. |
| 11054C0258/00N000 | Flanders | 1,586 m² | 1 · 195 m² | 8.3 m · 2 fl. |
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
19-05-2023 All shares are now held by a single shareholder
Technical details
{
"events": [
{
"kind": "eenhoofdigheid_declaration",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Herbert HOUBEN",
"firm_city": null,
"firm_name": null,
"office_city": "Genk",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-05-19",
"filing_date": "2023-05-16",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2023-05-10",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0660.595.140",
"name_full": "Dr. Daan DETROYER Nefrologie",
"legal_form": "BV",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Accountantskantoor REYNDERS \u0026 CO CV",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expeditie",
"geco\u00F6rdineerde statuten"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "Dr. Daan DETROYER",
"role": "aandeelhouder",
"n_shares": 100,
"share_class": null
}
],
"share_classes_after": [
{
"n_shares": 100,
"class_name": "Aandelen",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}| Legal nameNL | Dr. Daan DETROYER Nefrologie |